ArticleImmunity, inflammation and disease2026
Juanbi Tang Attenuates Intervertebral Disc Degeneration by Suppressing p38MAPK/NF-κB Signaling and Activating Atg5-Dependent Autophagy to Promote Macrophage M2 Polarization: In Vivo and In Vitro Evidence.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundIntervertebral disc degeneration (IDD) is driven by macrophage-mediated inflammation involving the p38MAPK/NF-κB signaling pathway and impaired autophagic flux. Juanbi Tang (JBT), a classical eleven-herb Chinese formula documented since 1732 CE for the treatment of Bi syndrome (a traditional diagnosis encompassing painful musculoskeletal obstruction conceptually corresponding to degenerative spinal conditions), demonstrates clinical anti-inflammatory activity; however, its molecular mechanism in IDD remains uncharacterized.
methodsJBT chemical composition was characterized by HPLC fingerprinting with osthole as quantitative reference standard (inter-batch RSD 2.3%) in accordance with the 2020 Chinese Pharmacopoeia, and quality control was extended beyond a single marker constituent by multi-component fingerprint similarity analysis using the cosine angle and correlation coefficient methods. A male Sprague-Dawley rat annular puncture IDD model (five groups: Sham, IDD, IDD + JBT, IDD + 3-methyladenine [3-MA], and IDD + JBT + 3-MA) was evaluated by MRI, CT, Safranin O-Fast Green, Masson trichrome and hematoxylin and eosin staining. LPS-stimulated (1 μg/mL) primary rat nucleus pulposus (NP) cells and murine RAW264.7 macrophages - including Atg5-overexpressing (Atg5-OE) and knockdown (Atg5-KD) variants - were used for in vitro mechanistic studies. Endpoints included apoptosis, mitochondrial membrane potential (ΔΨm), reactive oxygen species (ROS), macrophage M1/M2 polarization, ELISA cytokine quantification and Western blot pathway analysis.
resultsIn vivo, JBT significantly improved Pfirrmann grade, disc height index, Safranin O staining intensity, Masson-stained collagen content and Thompson grade, with concomitant suppression of serum TNF-α and restoration of IL-10; all benefits were partially abrogated by 3-MA co-administration. JBT suppressed p-p38MAPK and p-NF-κB p65 and restored the COL II/MMP-13 balance in disc tissue. In NP cells, JBT reduced total apoptosis from 29.1% to 14.5%, restored ΔΨm, attenuated ROS accumulation, reversed the Bax/Bcl-2 ratio, and activated autophagy (LC3-II ↑ , p62 ↓ ). In RAW264.7 macrophages, JBT promoted M2 polarization (CD206
conclusionsJBT attenuates IDD through coordinated suppression of macrophage-driven inflammation and activation of autophagy, providing mechanistic support for its clinical application in musculoskeletal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.